SynthesisJournal of translational medicine2025
Factors affecting survival in patients with colorectal cancer: an umbrella review.
Synthesis in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors in colorectal cancer.Frontiers in immunology · 2026Pooled it
- Integrating Blood-Based Immune-Inflammation Biomarkers into Artificial Intelligence-Driven Prognostic Models in Oncology.International journal of molecular sciences · 2026Review
- Overstaging of the mesorectal fascia following neoadjuvant therapy and its impact on therapeutic management: a single-center retrospective cohort study of 506 mesorectal fascia positive patients.Journal of gastrointestinal oncology · 2026Article
- Differential Oxidative Stress Profiles in Circulating and Peritumoral Adipose Tissue Across Stages of Colorectal Cancer.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study aimed to evaluate the strength and validity of the evidence for reported associations between multiple factors and colorectal cancer (CRC) survival.
methodsWe searched PubMed, Embase, Cochrane Database of Systematic Reviews from inception to 20 June 2024 for systematic reviews and meta-analyses of observational studies on factors and CRC prognosis. The quality of the methodology was evaluated using A Measurement Tool to Assess systematic Reviews 2 (AMSTAR-2).
results90 meta-analyses investigated 191 associations (123 main evidence and 68 supplementary evidence) with CRC overall survival (OS). Factors were categorized into: demographic characteristic, perioperative condition, pathology of neoplasia, clinical laboratory indicators, comorbidities, behavior patterns and others. Totally, 6 associations were recommended as strong evidence (class I). While the presence of chemotherapy-induced neutropenia (CIN) (hazard ratio [HR] = 0.40, 95% confidence interval [CI] 0.32-0.51) denoted a better OS outcome, the existence of log odds of positive lymph nodes (LODDS) (HR = 3.49, 95% CI 2.88-4.23), liver cirrhosis (HR = 3.10, 95% CI 2.68-3.59) and the increment of metastatic lymph node ratio (mLNR) (HR = 1.62, 95% CI 1.39-1.88), pretreatment neutrophils-lymphocytes ratio (NLR) (HR = 2.17, 95% CI 1.83-2.58) and pretreatment lymph node ratio (LNR) (HR = 3.13, 95% CI 2.36-4.15) were considered as poor predictors of OS. Notably, 2 strong evidence was also found in supplementary evidence including extranodal tumor deposits (ENTDs) (HR = 1.72, 95% CI 1.46-2.04) and absolute monocyte count (AMC) (HR = 1.83, 95% CI 1.47-2.29).
conclusionBeyond high-risk pathological signs of lymph node status and ENTDs, optimizable and cost-effective laboratory indicators, such as CIN, NLR, LNR and AMC, may effectively predict the prognosis of CRC. Furthermore, our study provides valuable insights for stratified CRC patient management, reinforcing the development of evidence-based prognostic survival strategies and recommendations.
trial registrationThis protocol was registered with PROSPERO under CRD42024560003.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.